Drug Guide

Generic Name

Trandolapril; Verapamil Hydrochloride

Brand Names Tarka, Trandolapril And Verapamil Hydrochloride

Classification

Therapeutic: Antihypertensive

Pharmacological: ACE inhibitor and calcium channel blocker

FDA Approved Indications

  • Hypertension
  • Chronic Stable Angina

Mechanism of Action

Trandolapril, an ACE inhibitor, reduces angiotensin II formation, lowering blood pressure and decreasing afterload. Verapamil, a calcium channel blocker, inhibits calcium influx into vascular smooth muscle and cardiac cells, leading to vasodilation and decreased heart rate.

Dosage and Administration

Adult: Typically, 2-4 mg once daily, titrated based on response.

Pediatric: Not approved for pediatric use.

Geriatric: Start at lower doses due to increased sensitivity and risk of hypotension.

Renal Impairment: Use caution; dose adjustments may be required.

Hepatic Impairment: Adjust dosage accordingly; cautious use recommended.

Pharmacokinetics

Absorption: Well absorbed after oral administration.

Distribution: Widely distributed, blood protein binding approximately 70-80%.

Metabolism: Metabolized in the liver, primarily via CYP3A4.

Excretion: Excreted mainly in urine and feces.

Half Life: Approximately 24 hours for both components.

Contraindications

  • History of angioedema related to previous ACE inhibitor or calcium channel blocker therapy.
  • Severe hypotension.
  • Obstruction of the outflow tract from the ventricles.
  • Known hypersensitivity to components.

Precautions

  • Use caution in volume-depleted patients, hepatic or renal impairment, and in pregnancy (see pregnancy category).

Adverse Reactions - Common

  • Dizziness (Common)
  • Headache (Common)
  • Hypotension (Common)
  • Peripheral edema (Common)

Adverse Reactions - Serious

  • Angioedema (Rare)
  • Severe hypotension (Rare)
  • Bradycardia or heart block with verapamil (Rare)

Drug-Drug Interactions

  • Other antihypertensives, diuretics, rifampin (affects metabolism), drugs that increase risk of hyperkalemia.

Drug-Food Interactions

  • Potassium-rich foods or supplements (risk of hyperkalemia).

Drug-Herb Interactions

  • St. John’s Wort (may decrease effectiveness).

Nursing Implications

Assessment: Monitor blood pressure, heart rate, renal function, and serum electrolytes.

Diagnoses:

  • Risk for hypotension
  • Risk for electrolyte imbalance
  • Ineffective peripheral tissue Perfusion

Implementation: Administer as directed, monitor vital signs regularly, check labs periodically.

Evaluation: Assess for blood pressure control, adverse effects, and symptoms of angioedema or heart failure.

Patient/Family Teaching

  • Take medication exactly as prescribed.
  • Do not discontinue abruptly.
  • Report signs of swelling, difficulty breathing, or chest pain.
  • Limit potassium-rich foods and monitor fluid intake.

Special Considerations

Black Box Warnings:

  • Fetal toxicity; discontinue as soon as pregnancy is detected.

Genetic Factors: Variability in CYP3A4 activity may affect metabolism.

Lab Test Interference: ACE inhibitors may affect renal function tests and serum potassium.

Overdose Management

Signs/Symptoms: Severe hypotension, bradycardia, AV block, or respiratory depression.

Treatment: Administer intravenous fluids, vasopressors for hypotension, atropine for bradycardia, and supportive care as needed.

Storage and Handling

Storage: Store at room temperature, 20-25°C, away from moisture and light.

Stability: Stable under recommended conditions.

This guide is for educational purposes only and is not intended for clinical use.